Agomelatine and Melatonin Interactions
There are no documented clinically significant drug-drug interactions between agomelatine and melatonin, though combining these agents is not routinely recommended due to overlapping mechanisms of action at melatonin receptors and lack of clinical trial data on their co-administration.
Pharmacological Overlap
Agomelatine functions as a melatonin receptor agonist (MT1/MT2) combined with 5-HT2C receptor antagonist properties 1. This dual mechanism distinguishes it from melatonin itself, which acts solely as a melatonin receptor agonist 2. When considering their interaction potential:
- Receptor-level interaction: Both compounds activate the same MT1/MT2 receptors, theoretically creating additive effects at these sites 1, 3
- Functional redundancy: The melatonergic component of agomelatine may render additional melatonin supplementation pharmacologically redundant
- Distinct pharmacodynamics: Agomelatine's 5-HT2C antagonism provides effects on dopamine and noradrenaline release that melatonin lacks 1, 4
Clinical Evidence Gap
No clinical trials have specifically evaluated the safety or efficacy of combining agomelatine with melatonin. The available evidence shows:
- Sleep medicine guidelines mention both agents separately for circadian rhythm disorders but provide no guidance on combination therapy 5
- Insomnia treatment guidelines note melatonin has "small effects on sleep latency, with little effect on WASO or TST" 2 but do not address its use with agomelatine
- One systematic review on preventing seasonal affective disorder found only one agomelatine trial and zero melatonin trials meeting inclusion criteria, with no combination studies 6
Theoretical Safety Considerations
While no specific drug interaction warnings exist, consider:
- Additive sedation: Both agents may enhance sleep propensity, potentially increasing daytime somnolence risk
- Circadian effects: Combining two melatonergic agents could theoretically produce excessive phase-shifting, though this remains speculative
- No documented serious interactions: Neither FDA labeling for agomelatine-related compounds 7 nor clinical guidelines 2, 8, 2 identify melatonin as a contraindicated combination
Practical Recommendations
If a patient is taking agomelatine for depression with circadian features, adding melatonin is generally unnecessary given agomelatine's inherent melatonergic activity 9, 3. However, if combination is considered:
- Monitor for excessive sedation or daytime drowsiness
- Use the lowest effective melatonin dose (typically 2-3 mg) if trialing combination
- Time administration appropriately (both typically given in evening)
- Reassess need for dual therapy after 2-4 weeks
Common pitfall: Assuming melatonin supplementation will enhance agomelatine's antidepressant effects—the 5-HT2C antagonism, not melatonergic activity, primarily drives agomelatine's mood benefits 1, 4.